PE20091925A1 - Derivados de indazol sustituidos con fenilo o benzodioxinilo - Google Patents
Derivados de indazol sustituidos con fenilo o benzodioxiniloInfo
- Publication number
- PE20091925A1 PE20091925A1 PE2009000705A PE2009000705A PE20091925A1 PE 20091925 A1 PE20091925 A1 PE 20091925A1 PE 2009000705 A PE2009000705 A PE 2009000705A PE 2009000705 A PE2009000705 A PE 2009000705A PE 20091925 A1 PE20091925 A1 PE 20091925A1
- Authority
- PE
- Peru
- Prior art keywords
- benzodioxin
- indazol
- benzamide
- amino
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
REFERIDA A UN DERIVADO DE INDAZOLILO DE FORMULA (Ib), DONDE A ES ALQUILO C1-C4, ALCOXI C1-C4 O HALOALQUILO C1-C4; R3 ES HETEROARILO C5-C10; W ES FENILO SUSTITUIDO CON -C(O)NR7R8; R7 ES H O ALQUILO C1-C4; R8 ES H, ALQUILO C1-C6, CICLOALQUILO C3-C7, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 3-(5-{[(1R,2S)-2-[(2,2-DIFLUOROPROPANOIL)AMINO]-1-(2,3-DIHIDRO-1,4-BENZODIOXIN-6-IL)PROPIL]OXI}-1H-INDAZOL-1-IL)-N-[(3S)-1,1-DIOXIDOTETRAHIDROTIOFEN-3-IL]BENZAMIDA, 3-(5-{[2-[(2,2-DIFLUOROPROPANOIL)AMINO]-1-(2,3-DIHIDRO-1,4-BENZODIOXIN-6-IL)PROPIL]OXI}-1H-INDAZOL-1-IL)-N-[1,1-DIOXIDOTETRAHIDROTIOFEN-3-IL]BENZAMIDA, 3-[5-({(1R,2S)-1-(4H-1,3-BENZODIOXIN-7-IL)-2-[(2,2-DIFLUOROPROPANOIL)AMINO]PROPIL}OXI)-1H-INDAZOL-1-IL]-N-[(3R)-1,1-DIOXIDOTETRAHIDROTIOFEN-3-IL]BENZAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE LOS RECEPTORES DE GLUCOCORTICOIDES Y SON UTILES COMO ANTIINFLAMATORIOS, ANTIALERGICOS, INMUNOSUPRESORES Y ANTIPROLIFERATIVOS
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5461608P | 2008-05-20 | 2008-05-20 | |
US8031208P | 2008-07-14 | 2008-07-14 | |
US14477609P | 2009-01-15 | 2009-01-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20091925A1 true PE20091925A1 (es) | 2010-01-24 |
Family
ID=41340347
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2009000705A PE20091925A1 (es) | 2008-05-20 | 2009-05-20 | Derivados de indazol sustituidos con fenilo o benzodioxinilo |
PE2009000706A PE20091974A1 (es) | 2008-05-20 | 2009-05-20 | Derivados de indazoles sustituidos con fenil o piridinilo |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2009000706A PE20091974A1 (es) | 2008-05-20 | 2009-05-20 | Derivados de indazoles sustituidos con fenil o piridinilo |
Country Status (42)
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO2754B1 (en) * | 2006-12-21 | 2014-03-15 | استرازينكا ايه بي | Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders |
CN104387382A (zh) | 2008-03-24 | 2015-03-04 | 梅迪维新技术公司 | 吡啶并[3,4-b]吲哚和应用方法 |
UY31831A (es) * | 2008-05-20 | 2010-01-05 | Astrazeneca Ab | Derivados de indazoles sustituidos con fenilo o piridinilo |
MX2011011079A (es) | 2009-04-30 | 2011-11-04 | Basf Se | Procedimiento para preparar compuestos de isoxazolina sustituidos y sus precursores. |
WO2011061527A1 (en) * | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
FR2955105B1 (fr) | 2010-01-11 | 2012-04-20 | Arkema France | Procede de preparation d'aminoethyl imidazolidone ou de son thiocarbonyle |
CA2801516A1 (en) | 2010-06-23 | 2011-12-29 | Basf Se | Process for producing imine compounds for combating invertebrate pests |
EP2635552A2 (en) | 2010-11-03 | 2013-09-11 | Basf Se | Method for preparing substituted isoxazoline compounds and their precursors 4-chloro, 4-bromo- or 4-iodobenzaldehyde oximes |
GB201021979D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | New compound |
GB201021992D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | Compound |
WO2012112966A1 (en) | 2011-02-18 | 2012-08-23 | Medivation Technologies, Inc. | Compounds and methods for treatment of hypertension |
US9974759B2 (en) | 2013-05-31 | 2018-05-22 | Indiana University Research And Technology Corporation | Beta 2 adrenoceptor antagonists for treating orthostatic hypotension |
MX2017003697A (es) * | 2014-09-26 | 2017-06-26 | Astrazeneca Ab | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y uso como moduladores selectivos de glucorticoides (sgrm). |
WO2016124722A1 (en) * | 2015-02-06 | 2016-08-11 | Astrazeneca Ab | A process for the preparation of 3-5-{[(1r,2s)-2-[(2,2-difluoropropanyl)amino]-1 -(2,3-dihydro-1,4-benzodioxin-6-yl]propyl]oxy}-1h-indazol-1-yl)-n-[(3r)-tetrahydrofuran-3-yl] benzamide |
GB201511382D0 (en) | 2015-06-29 | 2015-08-12 | Imp Innovations Ltd | Novel compounds and their use in therapy |
HUE048410T2 (hu) * | 2015-09-15 | 2020-07-28 | Leo Pharma As | Nem szteroid glükokortikoid receptor modulátorok helyi gyógyszer bejuttatásra |
WO2017161518A1 (en) | 2016-03-23 | 2017-09-28 | Astrazeneca Ab | New physical form |
CA3014357C (en) | 2016-03-24 | 2020-07-28 | Astrazeneca Ab | Crystalline form of n-cyclopropyl-3-fluoro-4-methyl-5-[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxo-1(2h)-pyrazinyl]benzamide |
CN106083837B (zh) * | 2016-05-27 | 2018-08-31 | 浙江普洛得邦制药有限公司 | 一种噁唑烷酮类抗菌药物及其中间体的制备方法 |
WO2019121606A1 (en) * | 2017-12-18 | 2019-06-27 | Grünenthal GmbH | Substituted pyrrolidine amides i |
TW201927769A (zh) * | 2017-12-18 | 2019-07-16 | 德商歌林達有限公司 | 經取代之吡咯啶醯胺ii |
JP7446316B2 (ja) | 2019-01-11 | 2024-03-08 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 置換ピロリジンアミドiii |
WO2020254552A2 (en) | 2019-06-19 | 2020-12-24 | Grünenthal GmbH | Substituted pyrrolidine amides v |
ES2946888T3 (es) | 2019-06-19 | 2023-07-27 | Gruenenthal Gmbh | Pirrolidina-amidas sustituidas IV |
US20230167068A1 (en) * | 2019-12-31 | 2023-06-01 | Medshine Discovery Inc. | Benzopyrazole compound |
EP4178954A1 (en) | 2020-07-09 | 2023-05-17 | Grünenthal GmbH | Substituted pyrrolidine amines and amides as mediator of the glucocortoid receptor |
WO2023274040A1 (zh) * | 2021-06-28 | 2023-01-05 | 南京明德新药研发有限公司 | 一种三唑并吡啶取代的吲唑类化合物的晶型及其制备方法 |
KR102571432B1 (ko) * | 2023-02-08 | 2023-08-29 | 주식회사 에스씨엘테라퓨틱스 | 인다졸릴에스테르 및 아미드 유도체를 포함하는 암 치료용 조성물 |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB607840A (en) | 1946-02-12 | 1948-09-06 | Bristol Aeroplane Co Ltd | Improvements in or relating to means for feeding ammunition to automatic fire arms |
US3992441A (en) * | 1972-12-26 | 1976-11-16 | Pfizer Inc. | Sulfamylbenzoic acids |
DE3000377A1 (de) | 1980-01-07 | 1981-07-09 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel |
DE3514696A1 (de) | 1985-04-24 | 1986-11-06 | Bayer Ag, 5090 Leverkusen | N-indolylethyl-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung |
DE3535167A1 (de) | 1985-10-02 | 1987-04-09 | Boehringer Mannheim Gmbh | Neue sulfonyl-phenyl(alkyl)amine, verfahren zu ihrer herstellung sowie arzneimittel |
DE3632329A1 (de) | 1986-09-24 | 1988-03-31 | Bayer Ag | Substituierte phenylsulfonamide |
TW224462B (es) | 1992-02-24 | 1994-06-01 | Squibb & Sons Inc | |
NZ247440A (en) | 1992-05-06 | 1995-04-27 | Squibb & Sons Inc | Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof |
CA2114981A1 (en) | 1993-02-09 | 1994-08-10 | Kazumi Ogata | Quinolonecarboxylic acid derivatives |
DE4323916A1 (de) | 1993-07-16 | 1995-01-19 | Basf Ag | Substituierte 2-Phenylpyridine |
EP0679641B1 (en) | 1993-07-26 | 2002-10-02 | Eisai Co., Ltd. | Sulfonamide and sulfonic ester derivatives each having tricyclic hetero ring |
WO1995006822A1 (en) | 1993-08-30 | 1995-03-09 | Airflow Research Manufacturing Corporation | Housing with recirculation control for use with banded axial-flow fans |
GB9504854D0 (en) | 1994-03-31 | 1995-04-26 | Zeneca Ltd | Nitrogen derivatives |
US5545669A (en) | 1994-06-02 | 1996-08-13 | Adams; Jerry L. | Anti-inflammatory compounds |
GB9417532D0 (en) | 1994-08-31 | 1994-10-19 | Zeneca Ltd | Aromatic compounds |
WO1996036595A1 (en) | 1995-05-19 | 1996-11-21 | Chiroscience Limited | 3,4-disubstituted-phenylsulphonamides and their therapeutic use |
TW523506B (en) | 1996-12-18 | 2003-03-11 | Ono Pharmaceutical Co | Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients |
TW542822B (en) | 1997-01-17 | 2003-07-21 | Ajinomoto Kk | Benzamidine derivatives |
US6372779B1 (en) | 1997-12-29 | 2002-04-16 | Ortho Pharmaceutical Corporation | Anti-inflammatory compounds |
US6200995B1 (en) | 1998-01-29 | 2001-03-13 | Tularik Inc. | PPAR-γ modulators |
DE19856475A1 (de) | 1998-11-27 | 2000-05-31 | Schering Ag | Nichtsteroidale Entzündungshemmer |
CA2372715A1 (en) | 1999-05-13 | 2001-04-12 | Shionogi & Co., Ltd. | Preventive or therapeutic drugs for diabetes |
US6569885B1 (en) | 1999-12-23 | 2003-05-27 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
MXPA03002080A (es) | 2000-09-11 | 2003-06-24 | Pfizer Prod Inc | Derivados de resorcinol. |
FR2815030A1 (fr) | 2000-10-05 | 2002-04-12 | Lipha | Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant et leur utilisation pour la preparation de medicaments |
US6838074B2 (en) * | 2001-08-08 | 2005-01-04 | Bristol-Myers Squibb Company | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent |
CA2460594A1 (en) | 2001-10-01 | 2003-04-10 | Taisho Pharmaceutical Co., Ltd. | Mch receptor antagonists |
CN1578767A (zh) | 2001-11-22 | 2005-02-09 | 小野药品工业株式会社 | 哌啶-2-酮衍生化合物及包含其作为活性成分的药学组合物 |
EA007099B1 (ru) | 2002-03-13 | 2006-06-30 | Янссен Фармацевтика Н. В. | Сульфонилпроизводные в качестве ингибиторов гистон-деацетилазы |
US7282591B2 (en) | 2002-04-11 | 2007-10-16 | Merck & Co., Inc. | 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
NZ566263A (en) | 2002-05-24 | 2009-09-25 | Millennium Pharm Inc | CCR9 inhibitors and methods of use thereof |
JP2004059116A (ja) | 2002-07-31 | 2004-02-26 | Sharp Corp | ディスプレイ用基板収納用トレイ及びディスプレイ用基板の取り出し機構並びにディスプレイ用基板の取り出し方法 |
US20050113450A1 (en) | 2002-08-23 | 2005-05-26 | Atli Thorarensen | Antibacterial agents |
DE60333371D1 (de) | 2002-08-29 | 2010-08-26 | Boehringer Ingelheim Pharma | 3-(sulfonamidoethyl)-indol-derivate zur verwendung als glucocorticoid-mimetika bei der behandlung von entzündlichen, allergischen und proliferativen erkrankungen |
US6894061B2 (en) | 2002-12-04 | 2005-05-17 | Wyeth | Substituted dihydrophenanthridinesulfonamides |
EP2415760A3 (en) | 2003-02-20 | 2012-02-22 | Encysive Pharmaceuticals, Inc. | CCR-9 antagonists |
GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
US7297709B2 (en) | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
US20040235892A1 (en) | 2003-05-22 | 2004-11-25 | Yujia Dai | Indazole and benzisoxazole kinase inhibitors |
WO2004110418A2 (en) | 2003-06-10 | 2004-12-23 | Kalypsys, Inc. | Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease |
US7393873B2 (en) | 2003-07-02 | 2008-07-01 | Merck & Co., Inc. | Arylsulfonamide derivatives |
CA2549651A1 (en) | 2003-12-19 | 2005-07-07 | Pfizer Inc. | Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity |
JP4829506B2 (ja) | 2004-02-17 | 2011-12-07 | 石原産業株式会社 | チオアミド系化合物又はその塩、並びにそれらを含有するサイトカイン産生抑制剤 |
CA2555914A1 (en) | 2004-03-08 | 2005-09-22 | Amgen Inc. | Therapeutic modulation of ppar (gamma) activity |
DE102004028862A1 (de) | 2004-06-15 | 2005-12-29 | Merck Patent Gmbh | 3-Aminoindazole |
SE0402635D0 (sv) | 2004-10-29 | 2004-10-29 | Astrazeneca Ab | Chemical compounds |
SE0402636D0 (sv) * | 2004-10-29 | 2004-10-29 | Astrazeneca Ab | Chemical compounds |
AU2005300150A1 (en) | 2004-10-29 | 2006-05-04 | Astrazeneca Ab | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases |
ES2414479T3 (es) | 2005-04-14 | 2013-07-19 | Glaxo Group Limited | Indazoles como ligandos del receptor de glucocorticoides |
AU2006257861A1 (en) | 2005-06-10 | 2006-12-21 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US7888381B2 (en) | 2005-06-14 | 2011-02-15 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof |
TW200815361A (en) * | 2005-10-20 | 2008-04-01 | Astrazeneca Ab | Chemical compounds |
GB0522880D0 (en) | 2005-11-09 | 2005-12-21 | Glaxo Group Ltd | Novel compounds |
US20090170898A1 (en) * | 2006-03-31 | 2009-07-02 | Malena Bengtsson | Sulphonamide Derivatives as Modulators of the Glucocorticoid Receptor |
US7943651B2 (en) * | 2006-04-20 | 2011-05-17 | Glaxo Group Limited | Compounds |
GB0607840D0 (en) | 2006-04-20 | 2006-05-31 | Glaxo Group Ltd | Novel compounds |
EP2043646B1 (en) | 2006-07-14 | 2012-05-16 | Eli Lilly And Company | (E)-N-{3-(8-Chloro-11H-10-oxa-1-aza- dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-phenyl} -methanesulfonamide as a GLUCOCORTICOID RECEPTOR MODULATOR AND METHODS OF USE |
GB0620385D0 (en) | 2006-10-13 | 2006-11-22 | Glaxo Group Ltd | Novel compounds |
GB0620406D0 (en) | 2006-10-13 | 2006-11-22 | Glaxo Group Ltd | Novel compounds |
EA200970401A1 (ru) | 2006-10-23 | 2009-10-30 | Мерк Энд Ко., Инк. | 2-[1-ФЕНИЛ-5-ГИДРОКСИ ИЛИ МЕТОКСИ-4-АЛЬФА-МЕТИЛГЕКСАГИДРОЦИКЛОПЕНТА[f]ИНДАЗОЛ-5-ИЛ] ЭТИЛФЕНИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ЛИГАНДОВ ГЛЮКОКОРТИКОИДНОГО РЕЦЕПТОРА |
JP2010508358A (ja) | 2006-11-01 | 2010-03-18 | ブリストル−マイヤーズ スクイブ カンパニー | グルココルチコイド受容体、AP−1、および/またはNF−κB活性の調節剤、並びにその使用 |
EP2094692B1 (en) | 2006-11-01 | 2012-11-28 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof |
US20120065173A1 (en) | 2006-11-23 | 2012-03-15 | Markus Berger | Chemical compounds |
TW200829578A (en) * | 2006-11-23 | 2008-07-16 | Astrazeneca Ab | Chemical compounds 537 |
US8658637B2 (en) | 2006-12-06 | 2014-02-25 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
JO2754B1 (en) * | 2006-12-21 | 2014-03-15 | استرازينكا ايه بي | Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders |
WO2008079073A1 (en) | 2006-12-22 | 2008-07-03 | Astrazeneca Ab | Indazolyl sulphonamide derivatives for the treatment of glucocorticoid receptor mediated disorders |
WO2008124745A1 (en) | 2007-04-10 | 2008-10-16 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
CA2683647A1 (en) | 2007-04-10 | 2008-10-16 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
GB0708858D0 (en) | 2007-05-08 | 2007-06-13 | Glaxo Group Ltd | Novel compounds |
DE102007029419A1 (de) | 2007-06-26 | 2009-01-02 | Emsland-Stärke GmbH | Filamentfaserschlichtemittel und Verwendung desselben |
GB0720549D0 (en) | 2007-10-19 | 2007-11-28 | Glaxo Group Ltd | Novel compounds |
GB0720546D0 (en) | 2007-10-19 | 2007-11-28 | Glaxo Group Ltd | Novel compounds |
GB0720557D0 (en) | 2007-10-19 | 2007-11-28 | Glaxo Group Ltd | Novel compounds |
GB0720556D0 (en) | 2007-10-19 | 2007-11-28 | Glaxo Group Ltd | Novel compounds |
GB0720544D0 (en) | 2007-10-19 | 2007-11-28 | Glaxo Group Ltd | Novel compounds |
GB0722211D0 (en) | 2007-11-12 | 2007-12-27 | Glaxo Group Ltd | Novel compounds |
GB0724254D0 (en) | 2007-12-12 | 2008-01-23 | Glaxo Group Ltd | Novel compounds |
CA2714607A1 (en) | 2008-02-26 | 2009-09-03 | Merck Sharp & Dohme Corp. | Hexahydrocyclopentyl[f]indazole carboxamides and derivatives thereof as selective glucocorticoid receptor modulators |
JP2011513409A (ja) | 2008-03-06 | 2011-04-28 | メルク・シャープ・エンド・ドーム・コーポレイション | 選択的グルココルチコイドレセプターモジュレーターとしてのヘキサヒドロシクロペンチル[f]インダゾールスルホンアミドおよびこれらの誘導体 |
UY31831A (es) * | 2008-05-20 | 2010-01-05 | Astrazeneca Ab | Derivados de indazoles sustituidos con fenilo o piridinilo |
-
2009
- 2009-05-19 UY UY0001031831A patent/UY31831A/es not_active Application Discontinuation
- 2009-05-19 TW TW098116533A patent/TWI445705B/zh active
- 2009-05-19 US US12/468,561 patent/US8211930B2/en active Active
- 2009-05-19 SA SA109300309A patent/SA109300309B1/ar unknown
- 2009-05-19 US US12/468,494 patent/US20100080786A1/en not_active Abandoned
- 2009-05-19 UY UY0001031832A patent/UY31832A/es not_active Application Discontinuation
- 2009-05-19 TW TW098116534A patent/TW200951114A/zh unknown
- 2009-05-20 KR KR1020107025957A patent/KR101593253B1/ko active IP Right Grant
- 2009-05-20 CN CN200980128406.5A patent/CN102099355B/zh active Active
- 2009-05-20 CA CA2724508A patent/CA2724508C/en active Active
- 2009-05-20 NZ NZ588994A patent/NZ588994A/xx unknown
- 2009-05-20 PE PE2009000705A patent/PE20091925A1/es active IP Right Grant
- 2009-05-20 AU AU2009249872A patent/AU2009249872A1/en not_active Abandoned
- 2009-05-20 MY MYPI2010005417A patent/MY173448A/en unknown
- 2009-05-20 JP JP2011510458A patent/JP2011520954A/ja active Pending
- 2009-05-20 AR ARP090101815A patent/AR071857A1/es active IP Right Grant
- 2009-05-20 AU AU2009249874A patent/AU2009249874B2/en active Active
- 2009-05-20 KR KR1020107025956A patent/KR20110007208A/ko not_active Application Discontinuation
- 2009-05-20 DK DK09750866.7T patent/DK2291369T3/en active
- 2009-05-20 PT PT97508667T patent/PT2291369E/pt unknown
- 2009-05-20 CL CL2009001247A patent/CL2009001247A1/es unknown
- 2009-05-20 ME MEP-2016-24A patent/ME02455B/me unknown
- 2009-05-20 PL PL09750866T patent/PL2291369T3/pl unknown
- 2009-05-20 EA EA201001683A patent/EA201001683A1/ru unknown
- 2009-05-20 WO PCT/SE2009/000267 patent/WO2009142571A1/en active Application Filing
- 2009-05-20 MX MX2010012390A patent/MX2010012390A/es not_active Application Discontinuation
- 2009-05-20 WO PCT/SE2009/000265 patent/WO2009142569A1/en active Application Filing
- 2009-05-20 EP EP13165585.4A patent/EP2620435A1/en not_active Withdrawn
- 2009-05-20 UA UAA201013070A patent/UA102543C2/uk unknown
- 2009-05-20 PE PE2009000706A patent/PE20091974A1/es not_active Application Discontinuation
- 2009-05-20 PA PA20098827101A patent/PA8827101A1/es unknown
- 2009-05-20 BR BRPI0912855A patent/BRPI0912855A2/pt not_active IP Right Cessation
- 2009-05-20 AR ARP090101814A patent/AR071856A1/es unknown
- 2009-05-20 CA CA2724584A patent/CA2724584A1/en not_active Abandoned
- 2009-05-20 MX MX2010012529A patent/MX2010012529A/es active IP Right Grant
- 2009-05-20 RS RS20160050A patent/RS54700B1/en unknown
- 2009-05-20 JP JP2011510459A patent/JP5579704B2/ja active Active
- 2009-05-20 EP EP09750864A patent/EP2291359A4/en not_active Withdrawn
- 2009-05-20 ES ES09750866.7T patent/ES2561598T3/es active Active
- 2009-05-20 PA PA20098827001A patent/PA8827001A1/es unknown
- 2009-05-20 BR BRPI0912878-6A patent/BRPI0912878B1/pt active IP Right Grant
- 2009-05-20 EA EA201001682A patent/EA018629B8/ru not_active IP Right Cessation
- 2009-05-20 CL CL2009001248A patent/CL2009001248A1/es unknown
- 2009-05-20 SI SI200931365T patent/SI2291369T1/sl unknown
- 2009-05-20 EP EP09750866.7A patent/EP2291369B1/en active Active
- 2009-05-20 CN CN200980128407XA patent/CN102112449A/zh active Pending
- 2009-05-20 HU HUE09750866A patent/HUE027217T2/en unknown
-
2010
- 2010-11-04 IL IL209122A patent/IL209122A0/en unknown
- 2010-11-04 CO CO10137241A patent/CO6351783A2/es not_active Application Discontinuation
- 2010-11-04 ZA ZA2010/07919A patent/ZA201007919B/en unknown
- 2010-11-04 ZA ZA2010/07918A patent/ZA201007918B/en unknown
- 2010-11-04 IL IL209121A patent/IL209121A/en active IP Right Grant
- 2010-11-04 CO CO10137238A patent/CO6331310A2/es active IP Right Grant
- 2010-11-19 CR CR11802A patent/CR11802A/es not_active Application Discontinuation
- 2010-11-19 DO DO2010000357A patent/DOP2010000357A/es unknown
- 2010-11-19 EC EC2010010620A patent/ECSP10010620A/es unknown
- 2010-11-19 HN HN2010002478A patent/HN2010002478A/es unknown
- 2010-11-19 CR CR11801A patent/CR11801A/es unknown
- 2010-11-19 SV SV2010003737A patent/SV2010003737A/es unknown
- 2010-11-19 SV SV2010003738A patent/SV2010003738A/es not_active Application Discontinuation
- 2010-11-19 EC EC2010010619A patent/ECSP10010619A/es unknown
- 2010-11-19 NI NI201000199A patent/NI201000199A/es unknown
- 2010-11-19 DO DO2010000359A patent/DOP2010000359A/es unknown
- 2010-12-06 MA MA33398A patent/MA32382B1/fr unknown
- 2010-12-06 MA MA33399A patent/MA32383B1/fr unknown
-
2011
- 2011-08-22 HK HK11108823.3A patent/HK1154580A1/zh unknown
-
2012
- 2012-06-06 US US13/490,204 patent/US8916600B2/en active Active
-
2014
- 2014-07-09 JP JP2014141429A patent/JP2014185188A/ja active Pending
- 2014-11-19 US US14/547,809 patent/US9512110B2/en active Active
-
2016
- 2016-01-22 HR HRP20160071TT patent/HRP20160071T1/hr unknown
- 2016-02-03 CY CY20161100092T patent/CY1117330T1/el unknown
- 2016-12-02 US US15/367,936 patent/US9738632B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20091925A1 (es) | Derivados de indazol sustituidos con fenilo o benzodioxinilo | |
PE20142099A1 (es) | Derivados de sulfonamida | |
PE20090297A1 (es) | Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis | |
PE20051173A1 (es) | Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3 | |
PE20081838A1 (es) | Derivados de ester o amida de imidazolilo como moduladores del receptor glucocorticoide | |
PE20091689A1 (es) | DERIVADOS DE 4-AMINOCICLOHEXANO SUSTITUIDO CON ACTIVIDAD SOBRE RECEPTORES µ Y ORL-1 | |
PE20080362A1 (es) | Derivados de ciclohexilpirazol-lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1 | |
PE20110684A1 (es) | Agonistas de los receptores de la melanocortina | |
PE20061038A1 (es) | Derivados del 1,5-difenil-1h-pirazol-3-il) oxadiazol como agentes antagonistas cb1 y su preparacion | |
AR072317A1 (es) | Dihidro oxo azinil isoxazolinas herbicidas de seis miembros | |
PE20080830A1 (es) | Compuestos derivados de sulfonilo que modulan el receptor cb2 | |
AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
PE20080858A1 (es) | Compuestos de n-aril pirazol y composiciones que los contienen | |
PE20021006A1 (es) | Derivados de 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la proteinquinasa | |
PE20081704A1 (es) | Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa | |
PE20071152A1 (es) | Compuestos derivados de azabiciclo[3.1.0]hex como moduladores de receptores de dopamina d3 | |
CO6251260A2 (es) | Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c. | |
PE20142185A1 (es) | Pirrolidina-2-carboxamidas sustituidas | |
PE20121058A1 (es) | Compuestos que modulan el receptor de androgenos | |
PE20131377A1 (es) | Triazina-oxadiazoles | |
AR059328A1 (es) | Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp | |
PE20081315A1 (es) | Derivados de benzimidazol como antagonistas de vr-1 | |
DE602006017543D1 (de) | Neue verbindungen | |
PE20060770A1 (es) | Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1 | |
PE20090592A1 (es) | Nuevos derivados de piperazina-amida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |